EYLEA® 8mg (114.3 mg/ml) is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME).
EYLEA® (aflibercept) 8mg
There are more than 54K people in Ireland who are blind or vision impaired and this number is on the rise as the population ages. The opthalmic outpatient services are under pressure due to large number of people on waiting lists.
What value would your patients place on an opportunity to minimise burden of treatment?
* Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q24 every 24 weeks (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.
What would extending intervals mean for patients like James?
Discover more on the nAMD page
What would it mean for patients like Aoife to visit the clinic less often than is currently expected?
Discover more on the DME page
Abbreviations
PP-EYL_8mg-IE-0150-1 | January 2026